Photomicrographs 

These show representative populations of your patient's malignant cells before and after exposure to targeted chemotherapy drugs. 

 

Drug Activity and Activity Category.  These columns report drug activity in the presence of your patient's actual tumor or endothelial cells.  Also reported is the implication for treatment.  In vitro test results are indexed to cohorts of previously-tested patients, based upon multiple closely-matching parameters. 

 

The circled features in this photomicrograph are endothelial cells which were killed in this patient’s assay by the drug bevacizumab (Avastin^©).  

Combined Report.  Results of anti-tyrosine kinase and anti-vascular assays are combined in a single assay report.

Concurrent EGFRx and AngioRx profiling allows for assessment of single agent and combination targeted therapies which have different therapy targets and potentially complementary mechanisms of activity.

 

Listing of targeted therapy  drugs and drug combinations that were tested.

 

Often, targeted therapy drugs are administered in combination with other targeted drugs or with standard anti-cancer drugs.  The AngioRx and EGFRx assays are the only methods in use today which have the ability to discriminate anti-tumor drug activity, in which cancer cells are killed directly by the drug, from anti-vascular drug activity, in which tumor cell death is the indirect result of endothelial cell inhibition – and to show specifically which drugs or drug combinations are  responsible.